The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Preliminary results for year ended 30 June 2015

19 Nov 2015 07:00

RNS Number : 2311G
Frontier IP Group plc
19 November 2015
 

19 November 2015

AIM: FIPP

 

Frontier IP Group plc

("Frontier IP", the "Group" or "the Company")

Audited final results for the year ended 30 June 2015

Frontier IP Group Plc is focused on the commercialisation of intellectual property

Financial Highlights

 

· Total revenue increased by 102% to £1,591,000 (2014: £786,000) - reflecting an unrealised profit on the revaluation of investments of £1,421,000 (2014: £608,000)

· Fair value of portfolio companies increased by 118% to £2,812,000 (2014: £1,291,000)

· Profit before tax of £647,000 (2014: £27,000)

· Basic earnings per share of 2.76p (2014: 0.13p)

· Cash balances at 30 June 2015 of £636,000 (2014: £587,000)

· Net assets per share as at 30 June 2015 of 20.9p (2014: 18.1p)

 

Operational Highlights

 

· Placing raised £854,000 (gross)

· Two new portfolio companies added, both from the University of Cambridge

· Portfolio companies Nandi Proteins Ltd and Alusid Ltd secured funding

· Post year-end, portfolio company Pulsiv Solar Ltd secured funding

 

Neil Crabb, Chief Executive Officer of Frontier IP, said,

"The Group is making good progress in line with its strategy. I am particularly pleased to report the growth in value of our portfolio, as evidenced by the recent fundraisings. We continue to see strong commercial progress in our Core Portfolio building the potential for further uplift in value."

 

Enquiries

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Company website: www.frontierip.co.uk

 

Cantor Fitzgerald Europe

(Nominated Adviser and Joint Broker)

T: 020 7894 7000

David Foreman, Catherine Leftley, Corporate Finance

David Banks, Corporate Broking

Peterhouse Corporate Finance Limited

(Joint Broker)

T: 020 7469 0935

Lucy Williams

Kreab

T: 020 7074 1800

Robert Speed, Matthew Jervois

 

 

 

Notes to Editors:

 

Frontier IP specialises in assisting institutions and companies in the commercialisation and exploitation of their intellectual property. It establishes formal and informal relationships with sources of exploitable IP, principally universities. Its core business is building and growing a portfolio of equity stakes in spin-out companies by taking an active involvement in the commercialisation and funding of these businesses. Frontier IP currently has seventeen companies in its portfolio, which exploit IP from a range of institutions. www.frontierip.co.uk 

 

Chairman's Statement

Performance

I am pleased to report that Frontier IP has made good progress during the year with a significant increase in the value of its portfolio and in extending its access to the highest quality IP.

 

Frontier IP's core strategy is to generate value by providing best practice IP commercialisation services to institutions and start-ups, to develop a portfolio of companies capable of commercial success and by providing access to capital for these portfolio companies. The Group has made progress in each of these areas over the year.

 

During the period we extended our sources of deal flow with the addition of two new start-up companies to our portfolio, both based on the work of academics at the Department of Chemical Engineering and Biotechnology at the University of Cambridge.

 

We have seen excellent progress in our Core Portfolio and we are pleased to report a 118% increase in the value of our portfolio overall.

 

We provided access to capital for three of our Core Portfolio companies. Nandi Proteins Limited and Alusid Limited both completed successful fundraisings during the period as did, after the year end, Pulsiv Solar Limited. All three fundraisings were achieved at significantly higher valuations, with the latter two driving increased total revenue for the year. Alusid Limited has since commissioned a pilot plant facility to commence manufacture of construction products from waste materials. Nandi continues to make good commercial progress receiving a high level of support from the Frontier IP team and anticipates a further fundraising at a price which would represent a substantial uplift to the last round.

 

Portfolio

In line with our move towards earning more significant equity holdings in spin-out companies, we received a 40% stake in each of our two most recent portfolio additions, Cambridge Sensor Innovation Limited (formerly Cambridge Sensor Technologies Limited) and Cambridge Simulation Solutions Limited. Both companies were formed to exploit technologies developed by academics at the Department of Chemical Engineering and Biotechnology at the University of Cambridge.

 

Our portfolio now comprises 17 companies and we look forward to increasing the number and size of our portfolio stakes as we continue to engage with a wide range of potential sources of commercialisable IP.

 

Results

For the year to 30 June 2015, total revenue increased by 102% to £1,591,000 (2014: £786,000) as a result of booking an unrealised profit of £1,421,000 (2014: £608,000) on the revaluation of investments, principally due to the movement in fair value of two portfolio companies - Alusid Limited and Pulsiv Solar Limited - following successful fundraisings, with Pulsiv Solar's fundraising completing post year end. Revenue from services, principally board retainers, fund management fees and license income, decreased by 4% to £170,000 (2014: £178,000).

 

The fair value of our portfolio increased by 118% to £2,812,000 (2014: £1,291,000).

 

Profit before tax increased to £647,000 (2014: £27,000) reflecting the increased revenue offset by the cost of additional resources. The profit per share was 2.76p (2014: 0.13p).

 

Outlook

Looking ahead, we are working on a number of new opportunities and intend to continue to grow our portfolio by taking more significant stakes and extending our sources of deal flow. In line with our strategy of broadening the range of capital available to our portfolio companies, we expect to see further portfolio fundraisings during the current financial year. We look forward to seeing further progress in these areas over the new financial year.

 

 

Andrew Richmond

Chairman

 

Our Performance

Chief Executive Officer's Statement

The Group is making good progress in line with its strategy. I am particularly pleased to report the growth in value of our portfolio, as evidenced by the recent fundraisings. We continue to see strong commercial progress in our Core Portfolio building the potential for further uplift in value.

 

Key Performance Indicators

The key performance indicators for the Group are:

 

KPI

Description

2015 Performance

Change in fair value of the portfolio

Movement in the value of equity in the portfolio

£2,812,000 (2014: £1,291,000)

Growth in total revenue

Growth in the aggregate of revenue from services and change in fair value of the portfolio

£1,591,000 (2014: £786,000)

Profit

Profit before tax for the year

£647,000 (2014: £27,000)

Net Assets

Value of the Group's assets less the value of its liabilities

£5,557,000 (2014: £4,069,000)

Total initial equity in new portfolio companies

Aggregate percentage equity earned from new portfolio companies during the year

80% (2014: 31%)

 

The Chairman's Statement and Operational Review contains information on progress in the business during the year.

 

The Group's services revenue for the year to 30 June 2015 decreased to £170,000 (2014: £178,000) and, with administrative expenses of £945,000 (2014: £769,000), the Group continues to consume significant cash from operating activities. However, the Directors continue to pursue opportunities that will assist in closing the gap.

 

Operational Review

Corporate

Frontier IP completed a placing in April 2015 to support the development and growth of its relationships, advisory roles and portfolio companies. The placing comprised 4,066,667 new ordinary shares of 10p at a price of 21p per share, raising £854,000 before expenses.  

 

Portfolio

The Group added two new spin-out companies to its portfolio during the year. These were Cambridge Simulation Solutions Limited and Cambridge Sensor Innovation Limited (formerly Cambridge Sensor Technologies Limited).

 

The Group received a 40% equity stake in Cambridge Simulation Solutions Limited, a spin-out from the University of Cambridge. Cambridge Simulation was established to exploit the technology developed by Dr. Vassilios Vassiliadis, a Senior Lecturer at the Department of Chemical Engineering and Biotechnology. Dr. Vassiliadis has developed a method to simulate and control complex chemical processes, which potentially has a wide range of commercial applications in industry, including the food and pharmaceutical sectors.

 

The Group more recently received a 40% equity stake in Cambridge Sensor Innovation Limited, established to exploit a number of technologies developed by Dr. Mark Williamson, a lecturer and researcher at the Department of Chemical Engineering and Biotechnology at the University of Cambridge. Dr. Williamson develops temperature and humidity sensors and control strategies for industrial processes in which the composition of the processing atmosphere is important.

 

During the year two of our portfolio companies Nandi Proteins Limited and Alusid Limited completed successful fundraisings, as did Pulsiv Solar Limited after the year end. Alusid Limited has since commissioned a pilot plant facility to commence manufacture of construction products from waste materials. Nandi continues to make good commercial progress receiving a high level of support from the Frontier IP team and anticipates a further fundraising at a price which would represent a substantial uplift to the last round.

 

Sources of IP

In line with reviewing and extending our portfolio pipeline for sources of high-quality IP we have this year added to our portfolio with two companies based on IP developed within the Department of Chemical Engineering and Biotechnology at the University of Cambridge.

 

Access to Funding

We continue to extend and make use of our network in managing funding rounds for our portfolio companies, with a particular focus on our Core Portfolio. The recent investments in Nandi Proteins, Pulsiv Solar and Alusid were a successful demonstration of this approach. Frontier IP is building an extensive network of funders ranging from institutions, industry investors through to private individuals.

 

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the year ended 30 June 2015

2015

2014

£'000

£'000

Revenue

Revenue from services

Other operating income

Unrealised profit on the revaluation of investments

170

 

1,421

178

 

608

Total revenue

1,591

786

Administrative expenses

(945)

(769)

Dividend income on financial assets at fair value through profit or loss

-

10

Profit from operations

646

27

Interest income on short term deposits

1

-

Profit from operations and before tax

647

27

Taxation

-

-

Profit and total comprehensive income attributable to

the equity holders of the parent

647

27

 

Profit per share attributable to the equity holders of the Company:

Basic earnings per share

2.76p

0.13p

Diluted earnings per share

2.71p

0.13p

 

All of the Group's activities are classed as continuing.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At 30 June 2015

2015

2014

£'000

£'000

Assets

Non-current assets

Tangible fixed assets

2

2

Goodwill

1,966

1,966

Financial assets at fair value through profit and loss

2,859

1,325

Trade receivables

29

86

4,856

3,379

Current assets

Trade receivables and other current assets

188

213

Cash and cash equivalents

636

587

824

800

Total assets

5,680

4,179

Liabilities

Current liabilities

Trade and other payables

(123)

(110)

(123)

(110)

Net assets

5,557

4,069

Equity

Called up share capital

2,660

2,253

Share premium account

5,200

4,794

Reverse acquisition reserve

(1,667)

(1,667)

Share based payment reserve

45

125

Retained earnings

(681)

(1,436)

Total equity

5,557

4,069

 

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the year ended 30 June 2015

 

 

Share capital

 

Share

premium

account

 

Reverse acquisition

reserve

Share-

based payment

reserve

 

 

Retained earnings

Total equity

attributable to

equity holders

of the Company

£'000

£'000

£'000

£'000

£'000

£'000

At 1 July 2013

1,305

4,457

(1,667)

119

(1,463)

2,751

Issue of shares

948

337

-

-

-

1,285

Share-based payments

-

-

-

6

-

6

Profit/total comprehensive income for the year

 

-

 

-

 

-

 

-

 

27

 

27

At 30 June 2014

2,253

4,794

(1,667)

125

(1,436)

4,069

Issue of shares

407

406

-

-

-

813

Share-based payments

-

-

-

28

-

28

Transfer on expiry of warrants in prior year

(108)

108

-

Profit/total comprehensive income for the year

 

-

 

-

 

-

 

-

 

647

 

647

At 30 June 2015

2,660

5,200

(1,667)

45

(681)

5,557

 

CONSOLIDATED STATEMENT OF CASH FLOWS

For the year ended 30 June 2015

2015

2014

£'000

£'000

Cash flows from operating activities

Cash used in operations

(730)

(617)

Taxation paid

-

-

 

Net cash used in operating activities

 

(730)

 

(617)

Cash flows from investing activities

Purchase of tangible fixed assets

(1)

(3)

Purchase of financial assets at fair value through profit and loss

 

 

 

(33)

 

(26)

 

Net cash used in investing activities

 

(34)

 

(29)

Cash flows from financing activities

Proceeds from issue of equity shares

854

1,142

Costs of share issue

(41)

(64)

 

Net cash generated from financing activities

 

813

 

1,078

 

Net increase in cash and cash equivalents

 

49

 

432

Cash and cash equivalents at beginning of year

587

155

 

Cash and cash equivalents at end of year

 

636

 

587

 

Cash used in operations

Profit before tax

647

27

Adjustments for:

Share-based payments

Depreciation

Fair value (gain) on financial assets through profit and loss

Cost of share issue

Changes in working capital:

28

2

(1,421)

-

6

1

(608)

26

Trade and other receivables

Trade and other payables

1

13

(93)

24

Cash flows from operating activities

 

(730)

 

(617)

 

NOTES

1. General information

 

This preliminary announcement was approved for issue by a duly appointed and authorised committee of the Board of Directors on 18 November 2015.

2. Basis of preparation

The financial information set out in this announcement does not constitute statutory financial statements for the year ended 30 June 2015 or 30 June 2014. The report of the auditor on the statutory financial statements for the year ended 30 June 2015 and 30 June 2014 was not qualified, but drew attention by way of emphasis to the uncertainty regarding the Group's ability to generate sufficient working capital to support the ongoing requirements of the Group and the preparation of the financial statements on a going concern basis.

The report of the auditor on the statutory financial statements for each of the years ended 30 June 2015 and 30 June 2014 did not contain statements under section 498(2) or (3) of the Companies Act 2006. The statutory financial statements for the year ended 30 June 2014 have been delivered to the Registrar of Companies. The financial statements for the year ended 30 June 2015 will be delivered to the Registrar of Companies following the Company's Annual General Meeting.

Going Concern

The Group's strategy is to develop a growing portfolio of spin-out companies that will provide cash inflows through realisation of investments and in the meantime will make use of the Group's services in return for cash fees. However, based on forecast income and expenditure for the next 12 months, the Group's cash income will be insufficient to cover the Group's expenditure. Consequently, the Group will require to raise additional capital in order to continue in operational existence for at least the next 12 months. The Directors anticipate undertaking an equity placing by early 2016 and also intend to seek authority to allot securities at the forthcoming Annual General Meeting in December 2015. The Directors have concluded that the necessity to raise additional capital represents a material uncertainty that casts significant doubt upon the Group's ability to continue as a going concern and that should it be unable to raise further funds, the Group may be unable to realise its assets and discharge its liabilities in the normal course of business. Nevertheless, considering the success of previous fundraisings and the current performance of the business, the Directors have a reasonable expectation of raising sufficient additional capital to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the Group's financial statements.

 

While the financial information included in this preliminary announcement has been prepared in accordance with the recognition and measurement principles of International Financial Reporting Standards (IFRS) as adopted by the European Union, this announcement does not itself contain sufficient information to comply with IFRS.

3. Segmental information

The Group operates in one market sector, the commercialisation of university Intellectual Property, and wholly within the UK. Therefore, revenue, profit on ordinary activities before tax and net assets do not need to be analysed by segment.

 

4. Taxation

There is no charge to taxation for the year ended 30 June 2015 (2014: Nil) due to the Group making a taxable loss.

The Group's deferred tax assets, other than those relating to short term timing differences, are not recognised in accordance with Group policy.

5. Earnings per share

 

(a) Basic

 

Basic earnings per share is calculated by dividing the profit attributable to the shareholders of Frontier IP Group Plc by the weighted average number of shares in issue during the year.

Profit attributable to shareholders £'000

Weighted average number of shares

Basic earnings per share amount in pence

Year ended 30 June 2015

647

23,414,536

2.76

Year ended 30 June 2014

27

20,091,931

0.13

 

(b) Diluted

 

Diluted earnings per share is calculated by adjusting the weighted number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares. The Company has only one category of dilutive potential ordinary shares: share options. A calculation is done to determine the number of shares that could have been acquired at fair value (determined as the average annual market value share price of the Company's shares) based on the monetary value of the subscription rights attached to outstanding share options. The number of shares calculated as above is compared with the number of shares that would have been issued assuming the exercise of the share options.

Profit attributable to shareholders £'000

Weighted average number of shares adjusted for share options

Diluted earnings per share amount in pence

Year ended 30 June 2015

647

23,854,707

2.71

Year ended 30 June 2014

27

20,376,926

0.13

 

 

6. Availability of statutory financial statements

 

Copies of the full statutory financial statements will be available from the Company's offices at 93 George Street, Edinburgh EH2 3ES no later than 27 November 2015 and are available on its website at www.frontierip.co.uk 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLIFFILILALIE
Date   Source Headline
7th May 202410:15 amRNSTVG to collaborate with The Pirbright Institute
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.